SYS-CON MEDIA Authors: Kevin Benedict, Gilad Parann-Nissany, Michael Bushong, Eric Brown

News Feed Item

Investigation Report on China Adalimumab Market, 2010-2018

DUBLIN, March 28, 2014 /PRNewswire/ --

Dublin - Research and Markets (http://www.researchandmarkets.com/research/w69m87/investigation) has announced the addition of the "Investigation Report on China Adalimumab Market, 2010-2018" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )


Adalimumab is a TNF (tumor necrosis factor) inhibiting anti-inflammatory drug, the first fully human monoclonal antibody drug approved by the FDA. It was discovered through collaboration between BASF Bioresearch Corporation and Cambridge Antibody Technology in 1993, then further manufactured at BASF Bioresearch Corporation and developed by BASF Knoll (BASF Pharma) and, ultimately, manufactured and marketed by Abbott Laboratories after the acquisition of BASF Pharma by Abbott. In 2000 Abbott Laboratories took over Knoll with USD 6.9 billion. At the end of 2002 adalimumab was approved to the market by FDA.

As of 2008 adalimumab (produced by Abbott with the trade name ""Humira"") had been approved by FDA for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, moderate to severe chronic psoriasis and juvenile idiopathic arthritis. Adalimumab is the best seller in the world in recent years. It can satisfy many urgent clinical needs because of its wide range of indications. The global sales revenue of Humira in 2012 exceeded USD 9 billion, and it reached USD 10 billion in 2013. Humira was launched in China in August 2010. According to CRI's market investigation, the sales revenue of adalimumab in Chinese sample hospitals grew 20 times from 2010 to 2013. More than 10 million people in China have adalimumab indications.

Humira is expected to bring Abbott (now AbbVie) the total sales revenue of USD 100 billion before its patent expires in 2016. This has made Humira the primary target of pharmaceutical enterprises from the world. More than 20 enterprises worldwide are developing adalimumab generic drugs and many of them are Chinese enterprises.

Huahai Pharmaceutical announced in May 2013 that they signed a strategic alliance agreement with ONCOBIOLOGICS to jointly develop biological drugs. The agreement states that Huahai Pharmaceutical is bestowed with 100% marketing right of four monoclonal antibody biological drugs in China. If Huahai Pharmaceutical establishes joint ventures in the U.S. to develop the four monoclonal antibody biological drugs, it will have 51% of the marketing right in developed countries such as the U.S. and Europe. Meanwhile the company will jointly establish a biopharmaceutical company with ONCOBIOLOGICS in China to develop monoclonal antibody biological drugs and conduct industrialization technique application research.

In December 2013 Huahai was informed by Oncobiologics that the MAb biosimilar Humira® jointly developed was approved to launch phase I clinical trial by EMA (the European Medicines Agency) and FDA.


Key Topics Covered:

1 Relevant Concepts of Adalimumab

2 Market Overview of Adalimumab in China, 2010-2013

3 Investigation on Sales Value of Adalimumab in China, 2010-2013

4 Investigation on Market Share of Major Adalimumab Manufacturers in China, 2010-2013

5 Investigation on Market Size of Adalimumab by Dosage Form in China, 2010-2013

6 Reference Price of Adalimumab in China Adalimumab Hospital Market, 2013

7 Analysis on Major Adalimumab Manufacturers in China, 2010-2013

8 Prospect of China Adalimumab Market, 2014-2018


Companies Mentioned:

  • AbbVie
  • BASF Bioresearch Corporation
  • BASF Pharma
  • Huahai Pharmaceutical


For more information visit http://www.researchandmarkets.com/research/w69m87/investigation


Media Contact: Laura Wood , +353-1-481-1716, [email protected]

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.